Welcome to our dedicated page for Iqvia Hldgs news (Ticker: IQV), a resource for investors and traders seeking the latest updates and insights on Iqvia Hldgs stock.
IQVIA Holdings Inc. (IQV) delivers integrated healthcare insights through its unique combination of clinical research expertise and advanced data analytics. This news hub provides investors and industry professionals with timely updates on corporate developments shaping the life sciences sector.
Access official press releases and curated news coverage spanning clinical trial milestones, healthcare data partnerships, regulatory updates, and technology innovations. Our collection serves as a strategic resource for understanding IQVIA's role in optimizing drug development cycles and commercial decision-making.
Key content categories include earnings announcements, merger/acquisition activity, leadership changes, and analytical breakthroughs in real-world evidence applications. Bookmark this page for efficient tracking of IQVIA's progress in transforming clinical research through data-driven solutions.
IQVIA (NYSE:IQV) has been recognized as a 'front-runner generative AI leader' for the life sciences industry by Everest Group® in their report 'AI-deas to Action: Operationalizing Generative AI in Life Sciences.' IQVIA stands out as the only clinical research organization (CRO) to achieve the highest front-runner ranking among 15 evaluated companies.
The company's Healthcare-grade AI® solutions have demonstrated leadership in integrating generative AI capabilities across research and development stages, focusing on patient journey analysis, clinical trial design, product commercialization strategies, and market access insights. IQVIA AI Assistant, their interactive tool for healthcare and life sciences insight generation, recently received the PM360 Innovation Award in the AI Category.
IQVIA Holdings (NYSE:IQV) has scheduled its first-quarter 2025 financial results announcement for Tuesday, May 6, 2025, before market opening. The management team will host a conference call and webcast at 9:00 a.m. Eastern Time on the same day.
The earnings release and financial information will be available on IQVIA's Investor Relations website. Interested parties must pre-register for the conference call through a provided link, after which they will receive confirmation details including a unique passcode and registrant ID. A webcast replay will be accessible approximately two hours after the event concludes.
Biopharma R&D showed significant progress in 2024, with funding reaching a 10-year high of $102 billion, excluding pandemic peaks - a substantial increase from $71 billion in 2023. Clinical trial starts stabilized at 5,318, comparable to pre-pandemic levels of 5,316 in 2019.
The year saw 65 novel active substances launched globally, including breakthrough treatments in schizophrenia, MASH, rare neurological diseases, and non-oncology hematology. While this represents a decline from 80 launches in 2023, it surpasses pre-pandemic figures.
Notable improvements include increased Phase III trial success rates, though Phase I and II success rates declined. Inter-trial intervals improved to 17 months from the 2022 pandemic peak of 32 months. Companies are implementing productivity enablers including decision frameworks, clinical technologies, and artificial intelligence solutions to address R&D complexity amid economic and geopolitical challenges.
IQVIA (NYSE:IQV) has been recognized as a leader in the IDC MarketScape's 2024 assessment for decentralized clinical trial (DCT) technologies and consulting services. The company's leadership position is attributed to its extensive network of over 200 DCT consultants, comprehensive DCT-enabling technologies, and expertise in regulatory strategy implementation.
IDC's first assessment of DCT technology solutions highlights IQVIA's strengths in:
- Deep clinical and DCT implementation strategy expertise across therapeutic areas
- Healthcare-grade AI implementation across the value chain
- Novel GenAI tools for enhanced patient experience
- Country-wise regulatory strategy expertise
Decentralized clinical trials, which gained momentum during COVID-19, utilize telemedicine and mobile technologies to conduct trial activities remotely. This approach enables patient monitoring through wearable devices and digital tools, reducing the need for in-person site visits.
IQVIA Laboratories has launched Site Lab Navigator, an advanced solution suite featuring innovative e-Requisition technology to streamline clinical trial lab workflows. The new system enables electronic submission of requisitions and lab specimen management, replacing manual paper processes.
Key features include:
- Seamless portal integration via IQVIA's One Home for Sites™
- Real-time sample tracking with courier data
- Guided kit replacement and online order management
- Real-time data validation
- Guided data entry to reduce errors
- Online sample collection guidance
Several top 10 pharmaceutical companies have already adopted the platform, which aims to reduce site administrative burden, improve data integrity, and accelerate trial outcomes through automated workflows and real-time data validation.
IQVIA AI Assistant has been awarded the 2024 PM360 Innovation Award in the Artificial Intelligence category. Launched in September 2024, this revolutionary tool provides quick, precise answers to complex business questions through a conversational interface with advanced data science capabilities.
The AI Assistant builds on IQVIA's decade-long experience in artificial intelligence and Healthcare-grade AI™, which prioritizes data privacy, security, and regulatory compliance. Currently available solutions include IQVIA Orchestrated Analytics with AI Assistant and IQVIA ChannelDynamics® Verbatim with AI Assistant, with additional offerings planned for launch this year.
These solutions help life sciences companies integrate AI-driven insights into strategic decision-making, enhancing precision and efficiency in commercial analytics and market research. The recognition from PM360, a leading pharmaceutical industry journal, validates IQVIA's commitment to delivering AI solutions that maintain high standards of trust, scalability, and precision.
IQVIA Holdings (NYSE:IQV) has announced that Ron Bruehlman, executive vice president and chief financial officer, will be presenting at the TD Cowen Annual Health Care Conference. The presentation is scheduled for Tuesday, March 4, 2025, at 11:10 a.m. ET.
Investors and interested parties can access a live audio webcast of the presentation through IQVIA's Investor Relations website at http://ir.iqvia.com. A replay of the webcast will be made available following the presentation on the same day.
IQVIA (NYSE:IQV) has released its 2024 Sustainability Report, highlighting significant achievements across multiple areas. The company, which serves over 10,000 customers in more than 100 countries, reported notable progress in employee development, healthcare access, environmental impact, and technology innovation.
Key highlights include:
- Investment in 88,000 employees worldwide through education and development programs, with over 1,000 employees participating in leadership development annually
- Expansion of clinical trial diversity and geographic reach, including new sites in Africa and Latin America
- Achievement of 27% reduction in scope 1 and 2 greenhouse gas emissions from 2019 baseline
- Implementation of responsible AI initiatives, including the launch of IQVIA AI Assistant and establishment of the Center for Defensible AI
- Recognition as the No. 1 most admired company in Health Care: Pharmacy and Other Services category on Fortune's World's Most Admired Companies list for the fourth consecutive year
IQVIA reported strong Q4 and full-year 2024 results, with Q4 revenue reaching $3,958 million and full-year revenue of $15,405 million. The company's Q4 performance showed a GAAP Net Income of $437 million and Adjusted EBITDA of $996 million. Technology & Analytics Solutions (TAS) revenue grew 9.5% at constant currency to $1,658 million in Q4.
R&D Solutions achieved quarterly bookings exceeding $2.5 billion with a book-to-bill ratio of 1.20x and maintained a strong contracted backlog of $31.1 billion. The company demonstrated robust cash flow performance with full-year Operating Cash Flow of $2,716 million, up 26% year-over-year, and Free Cash Flow of $2,114 million, up 41%.
IQVIA reaffirmed its 2025 guidance, projecting revenue between $15,725-16,125 million, Adjusted EBITDA of $3,765-3,885 million, and Adjusted Diluted EPS of $11.70-12.10.
IQVIA (NYSE:IQV) has been ranked No. 1 in the Health Care: Pharmacy and Other Services category on the 2025 Fortune® World's Most Admired Companies™ list for the fourth consecutive year. This marks the company's eighth consecutive appearance on the prestigious list.
The company secured top positions in four key attributes: innovation, global competitiveness, people management, and use of corporate assets. The recognition was based on Fortune® and Korn Ferry's comprehensive survey of over 3,300 executives, analyzing 650 companies across nine different attributes, including global business effectiveness, talent management, investment value, and environmental responsibility.
IQVIA Chairman and CEO Ari Bousbib attributed this achievement to the company's employees' dedication to advancing their mission of accelerating innovation for a healthier world. The Fortune® World's Most Admired Companies™ list, established in 1997, serves as a definitive assessment of corporate reputations, evaluating companies based on their industry standing and broader business practices.
